How Should Functionally Equivalent Drugs be Reimbursed?
Tóm tắt
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year.
Tài liệu tham khảo
Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001 Apr; 84 Suppl. 1: 3–10.
Macdougall IC. Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl 2002 May; 61(80): 55–61
Elliott SG, Lorenzini T, Strickland T, et al. Rational design of novel erythropoiesis stimulating protein (Aranesp™)- a super-sialated molecule with increased biological activity [abstract]. Blood 2000; 96 (Suppl. 1): 82a–3a
Krantz SB. Erythropoietin. Blood 1991; 77(3): 419–34
Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology 1986 Sep; 172(3–5): 213–24.
Amgen Inc. ARANESP™ (darbepoetin alfa): prescribing information [online]. Available from URL: http://www.aranesp.com/professional/prescribing_information.jsp [Accessed 2005 Sep 27]
Darbepoetin alfa: just a me-too; no advantage in anaemia of chronic renal failure. Rev Prescr 2002 Jun; 22 (229): 420–23
Ortho Biotech. PROCRIT™ (epoetin alpha): full prescribing information [online]. Available from URL: http://www.procrit.com/common/prescribing-information/PROCRIT/PDF/ProcritBooklet.pdf [Accessed 2005 Sep 27]
Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for the treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741–7
Suranyi M, Walker R, Jackson L, et al. Novel erythropoiesis stimulating protein (NESP) administered once every other week corrects anemia in patients with early chronic kidney disease [abstract]. J Am Soc Nephrol 2001; 12: 364a
Petroff S, Germain M, O’Shea M, et al. Prolonged epoetin alfa dosing intervals in patients with pre-end stage renal disease (Pre-ESRD) [poster no. 0834]. Poster presented at: ASN/ISN World Congress of Nephrology; 2001 Oct 13–17; San Francisco (CA)
Amgen Inc. Epogen (epoetin alfa) for injection: summary of product characteristics. Thousand Oaks (LA): Amgen Inc., 1999
Rubin RJ. Final report on the evaluation of epoetin alfa and darbepoetin alfa. Baltimore (MD): Report prepared for the Centers for Medicare and Medicaid Services, 2002 Oct
United States Department of Health and Human Services. Centers for Medicare and Medicaid Services, Outpatient Prospective Payment System (OPPS), fact sheet, 2002 Oct 31 [online]. Available from URL: http://www.cms.hhs.gov/providers/hopps/default.asp? [Accessed 2005 Sep 27].
United States Department of Health and Human Services, Centers for Medicare and Medicaid Services. Fact sheet: payment for Epogen, Procrit, and Aranesp under the Medicare Outpatient Prospective Payment System (OPPS). Washington, DC: CMS, 2002 31 Oct. URL: http://www.cms.hhs.gov/regulations/hopps/changecy2003.asp
Centers for Medicare and Medicaid Services (CMS). OPPS rule 2004. Washington, DC: CMS, 2003 Nov
Centers for Medicare and Medicaid Services (CMS). OPPS Rule 2003. Washington DC: CMS, 2002 Nov
United States Food and Drug Administration. The Red Book. Rockville (MD): FDA, 2002
Centers for Medicare and Medicaid Services (CMS) [online]. Available from URL: http://www.cms.hss.gov/providers/drugs/descrsdp.asp [Accessed 2003 Dec 1]
Centers for Medicare and Medicaid Services (CMS). Program memorandum intermediaries/carriers: single drug pricer [online]. CMS-Pub. 60AB; Department of Health and Human Services, CMS, 2002 Dec 2. Available from URL: http://www.cms.org [Accessed 2005 Sep 30]
United States National Archives and Records Administration, Department of Health and Human Services. Centers for Medicare and Medicaid Services. 42 CFR Part 405: Medicare Program; Payment Reform for Part B Drugs; Proposed Rule. Federal Register Part IV, Vol. 68, No. 161, Wednesday, August 20th, 2003, Proposed Rules
United States National Archives and Records Administration, Department of Health and Human Services, Centers for Medicare & Medicaid Services. 42 CFR Parts 410 and 419: Medicare Program; Changes to the Hospital Outpatient Prospective Payment System and Calendar Year 2004 Payment Rates; Proposed Rule. Federal Register Part IV, Vol. 68, No. 155, Tuesday, August 12, 2003, Proposed Rules
National Comprehensive Cancer Network Clinical practice guidelines in oncology: cancer and treatment-related anemia Vol. 1. Rockledge, PA: National Comprehensive Cancer Network, Inc., January 2003.
Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40(1): 110–8
Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002 Oct; 16 (10 Suppl. 11): 23–9
Glaspy JA, Jadeja JS, Justice G, et al. A randomised, active-control, pilot trial of front loaded dosing regiments of darbepoetin alfa for the treatment of patients with anaemia during chemotherapy for malignant disease. Cancer 2003; 95(5): 1312–20
Hedenus M, Hansen S, Taylor R, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002 Oct; 119(1): 79–86
Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268–76
Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875–82
Smith RE Jr, Tchekmedyian NS, Chan D, et al. A dose- and schedule- finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88: 1851–8
Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94(16): 1211–20
Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy (RT) either concomitantly or sequentially with chemotherapy [abstract]. Blood 2000; 96 (11 Pt 2): 434a
Crawford J, Demetri G, Gabrilove J, et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 2002; 29(3 Suppl.): 69–74
Shasha D, George MJ, Harrison LB. Once weekly dosing of epoetin alfa increases hemoglobin levels and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy; Poster presented at the American Society of Hematology (ASH); 2000 Dec 3; San Fransisco (CA)
Pirker R, Vansteenkiste J, Gateley J, et al. A phase 3, double blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proc Am Soc Clin Oncol 2001; 20: 394a
Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15(3): 1218–34
Glaspy JA, Jadeja J, Justice G, et al. Darbepoetin alfa administered every 1 or 2 weeks alleviates anemia (with no loss of dose efficiency) in patients with solid tumors. American Society of Hematology 43rd Annual Meeting and Exposition; 2001 Dec 7–11; Orlando (FL)
Hedenus M, Glaspy JA, Dewey C, et al. Dose response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies. American Society of Hematology 43rd Annual Meeting and Exposition; 2001 Dec 7–11; Orlando (FL)
Patton J, Camp M, Kuzur M, et al. Epoetin alfa (Procrit) 60,000 U once-weekly followed by 120,000 U every three weeks to maintain hemoglobin levels in anemic cancer patients receiving chemotherapy [abstract]. Proc Am Soc Clin Oncol 2002; 21 (Pt 1 of 2): 368a
Patton J, Camp M, Kuzur M, et al. Epoetin alfa (Procrit) 60,000 U once-weekly followed by 120,000 U every three weeks to maintain hemoglobin levels in anemic cancer patients receiving chemotherapy. Poster presented at the 38th Ann Meet Am Soc Clin Oncol (ASCO); 2002 May 1–21; Orlando (FL)
Saag MS, Levine AM, Leitz GJ, et al. Once-weekly epoetin alfa increases hemoglobin and improves quality of life in anemic HIV+ patients. Poster presented at the 39th Annual Meeting of the Infectious Diseases Society of America; 2001 Oct 27, San Francisco (CA)
Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from aprospective community oncology study. J Clin Oncol 1998; 16(10): 3412–25
Sloan JA, Witzig TE, Silberstein P. Quality of life, blood transfusion and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase III randomized double-blind placebo-controlled study; Poster presented 44th Annual Meeting and Exposition of the American Society of Hematology (ASH); 2002 Dec 6–10; Philadelphia (PA)
Cleeland C, Demetri GD, Glasby J, et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis [abstract]. Proc Am Soc Clin Oncol 1999; 18: 574a
Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, bouble-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74
Silberstein PT, Witzig TE, Sloan JA, et al. Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group [abstract]. 38th Annual Meeting American Society of Clinical Oncology; 2002 May 18–21; Orlando (FL)
Glaspy JA, Jadeja JS, Justice G, et al. Optimising the treatment of anemia in cancer patients: a randomized, active-controlled study investigating the dosing of D-alfa. Poster presented at the 2002 Conference of the American Society of Clinical Oncology; 2002 May 18–21; Orlando (FL)
Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002; 22 (9 Pt 2): 160S–5S
Joy MS. Novel erythropoiesis-stimulating protein, an erythropoietin analogue with an extended half-life and less frequent dosing. Formulary 2001; 36: 19–25
Barnett AI, Cremieux PY. Dose conversion from Epoetin alfa to Darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis. Pharmacotherapy 2003; 23(5): 690–4
United States Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). Medical officer clinical review from the summary basis of approval for BLA 99-1492/STN103951, darbepoetin alfa. Prepared by Unger EF. Amgen Inc
Unites States Food and Drug Administration. Red Book Update. Rockville (MD): FDA, August 2002; 8: 20–59
Centers for Medicare and Medicaid Services. Medicare current beneficiary survey. Baltimore (MD): Centers for Medicare and Medicaid Services, 2002
Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004; 9: 451–8
Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003; 25(11): 2781–96